Can hepatic substrate excess, impaired muscle glucose uptake, stress-hormone signaling, and low lean-mass support reinforce insulin resistance and atherogenic dyslipidemia?

Metabolic syndrome and cardiovascular risk are heavily driven by the intersection of skeletal muscle dysfunction, hepatic lipid overload, and neuroendocrine signaling. The pathways linking hepatic substrate excess, impaired muscle glucose uptake, stress hormones, and low lean mass form a highly integrated network that reinforces both systemic insulin resistance and atherogenic dyslipidemia.

Clinical and metabolic evidence

• Skeletal muscle as a metabolic sink: Skeletal muscle is responsible for 70% to 80% of postprandial, insulin-stimulated glucose disposal. Low lean mass (sarcopenia) directly reduces the physical capacity for glucose clearance, worsening insulin sensitivity and elevating HOMA-IR.
• Protein intake and muscle preservation: Inadequate dietary protein intake compromises nitrogen balance and accelerates muscle loss. This metabolic impairment creates a feedback loop: insulin resistance restricts the muscle’s ability to utilize amino acids for protein synthesis, while the resulting loss of lean mass further degrades glycemic control.
• Dyslipidemia markers: Low lean mass and insufficient protein intake are strongly associated with higher triglyceride levels, unfavorable LDL subfractions, and elevated triglyceride-glucose (TyG) indices. Conversely, preserving lean mass through resistance training and protein intake above 0.8 g/kg/day significantly reduces circulating triglycerides and improves lipid profiles.

Mechanistic explanations

• Hepatic lipid accumulation: Hepatic substrate excess (driven by elevated free fatty acids, glucose, and fructose) leads to the accumulation of intrahepatic diacylglycerol (DAG) within the plasma membrane. DAG recruits and activates protein kinase C epsilon (PKCε), which phosphorylates and impairs the insulin receptor, causing hepatic insulin resistance.
• Carbohydrate shunting and de novo lipogenesis (DNL): When skeletal muscle glucose uptake and glycogen storage are impaired (due to GLUT4 transport defects or low muscle mass), postprandial dietary carbohydrates are redirected to the liver. This hepatic substrate overflow activates transcriptional lipogenic programs, driving DNL and the overproduction of large, triglyceride-rich VLDL1 particles.
• Stress-hormone receptor signaling: Progesterone and cortisol directly antagonize insulin action. Progesterone blunts post-receptor PI3K-Akt signaling and GLUT4 activation in skeletal muscle and adipose tissue. Simultaneously, chronic cortisol elevation promotes visceral adiposity and upregulates rate-limiting lipases (such as HSL and ATGL), flooding the liver with portal free fatty acids that fuel VLDL secretion and atherogenic dyslipidemia (characterized by elevated triglycerides, increased small, dense LDL, and low HDL).

Bottom line

The claim is fully supported. Impaired skeletal muscle glucose uptake and low lean mass act as primary upstream drivers that shunt excess carbohydrates to the liver, fueling de novo lipogenesis. This hepatic substrate excess induces hepatic insulin resistance via DAG-mediated PKCε activation, while stress-hormone signaling further accelerates systemic insulin resistance and drives atherogenic dyslipidemia through elevated portal free fatty acid flux.